Daphne Quimi - 06 Jan 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
4
Filing time
10 Jan 2022, 19:31:20 UTC
Previous filing
04 Jan 2022
Next filing
19 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Award $0 +8,400 $0.000000 8,400 06 Jan 2022 Common Stock 8,400 $19.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.